QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
NASDAQ:VIGL

Vigil Neuroscience (VIGL) Stock Price, News & Analysis

$3.41
+0.21 (+6.56%)
(As of 04:00 PM ET)
Today's Range
$3.19
$3.41
50-Day Range
$2.68
$3.48
52-Week Range
$2.53
$11.11
Volume
79,538 shs
Average Volume
111,349 shs
Market Capitalization
$122.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.40

Vigil Neuroscience MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.60 Rating Score
Upside/​Downside
414.8% Upside
$17.40 Price Target
Short Interest
Bearish
7.64% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.19mentions of Vigil Neuroscience in the last 14 days
Based on 20 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.56) to ($2.29) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.64 out of 5 stars

Medical Sector

575th out of 938 stocks

Biological Products, Except Diagnostic Industry

93rd out of 154 stocks

VIGL stock logo

About Vigil Neuroscience Stock (NASDAQ:VIGL)

Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101, a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 proof-of-concept trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also conducting IND-enabling studies with a novel small molecule TREM2 agonist program to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Watertown, Massachusetts.

VIGL Stock Price History

VIGL Stock News Headlines

Investors Alert: The Next Big Thing in Weight Loss
History shows biotech breakthroughs like this can turn small investments into staggering fortunes for those with the foresight to get in early. I've isolated the small company behind it all...
Vigil Neuroscience: Q4 Earnings Insights
Investors Alert: The Next Big Thing in Weight Loss
History shows biotech breakthroughs like this can turn small investments into staggering fortunes for those with the foresight to get in early. I've isolated the small company behind it all...
Vigil Neuroscience Appoints Petra Kaufmann As CMO
VIGL Vigil Neuroscience, Inc.
See More Headlines
Receive VIGL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vigil Neuroscience and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/28/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:VIGL
Fax
N/A
Employees
66
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$17.40
High Stock Price Target
$24.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+443.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

Net Income
$-68,310,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.31 per share

Miscellaneous

Free Float
23,876,000
Market Cap
$114.82 million
Optionable
Not Optionable
Beta
1.80
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Dr. Ivana Magovcevic-Liebisch J.D. (Age 57)
    Ph.D., President, CEO & Director
    Comp: $908.25k
  • Ms. Jennifer Ziolkowski CPA (Age 50)
    Chief Financial Officer
    Comp: $617.55k
  • Sharon Morani
    Senior Director of Facilities & Operations
  • Kelly Neelon Ph.D.
    Vice President of CMC & Technical Operations
  • Dr. David Gray Ph.D. (Age 49)
    Chief Scientific Officer
  • Ms. Leah Gibson
    Vice President of Investor Relations and Corporate Communications
  • Mr. Christopher Verni J.D. (Age 49)
    General Counsel & Corporate Secretary
  • April Effort M.B.A.
    M.S., VP & Head of Corporate Development
  • Mr. Evan A. Thackaberry DABT (Age 51)
    Ph.D., Senior VP & Head of Early Development
  • Christian Mirescu Ph.D.
    VP & Head of Neuroimmunology

VIGL Stock Analysis - Frequently Asked Questions

Should I buy or sell Vigil Neuroscience stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vigil Neuroscience in the last year. There are currently 1 sell rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" VIGL shares.
View VIGL analyst ratings
or view top-rated stocks.

What is Vigil Neuroscience's stock price target for 2024?

5 equities research analysts have issued twelve-month target prices for Vigil Neuroscience's stock. Their VIGL share price targets range from $4.00 to $24.00. On average, they predict the company's share price to reach $17.40 in the next year. This suggests a possible upside of 414.8% from the stock's current price.
View analysts price targets for VIGL
or view top-rated stocks among Wall Street analysts.

How have VIGL shares performed in 2024?

Vigil Neuroscience's stock was trading at $3.38 at the beginning of 2024. Since then, VIGL shares have increased by 0.0% and is now trading at $3.38.
View the best growth stocks for 2024 here
.

When is Vigil Neuroscience's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our VIGL earnings forecast
.

When did Vigil Neuroscience IPO?

Vigil Neuroscience (VIGL) raised $112 million in an IPO on Friday, January 7th 2022. The company issued 7,000,000 shares at $15.00-$17.00 per share.

Who are Vigil Neuroscience's major shareholders?

Vigil Neuroscience's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Citadel Advisors LLC (6.03%), Vanguard Group Inc. (2.23%), Vanguard Group Inc. (2.23%), Sphera Funds Management LTD. (1.49%), Northern Trust Corp (0.39%) and Bridgeway Capital Management LLC (0.37%). Insiders that own company stock include Christopher Verni, Clay Thorp, Evan Thackaberry, Ivana Magovcevic-Liebisch and Spyros Papapetropoulos.
View institutional ownership trends
.

How do I buy shares of Vigil Neuroscience?

Shares of VIGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VIGL) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners